Skip to main content

Table 5 Clinical response after 1 year, by therapy

From: Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab

  All therapies ADA MTX TCZ TOF
Patients (n) 149 49 23 50 27
Pretreatment DAS28-ESR 5.35 (4.40–6.45) 5.33 (4.34–627) 4.23 (3.84–5.12) 5.43 (4.57–6.51) 6.34 (5.74–7.11)
DAS28-defined remission Y N Y N Y N Y N Y N
Patients (n) 82 67 26 23 15 8 30 20 11 16
Pretreatment DAS28-ESR 5.00 (4.09–6.13)a 5.85 (4.90–6.77) 5.30 (4.06–5.83) 5.67 (4.82–6.77) 4.11 (3.75–4.43) 4.78 (4.24–5.27) 4.80 (4.23–6.27)b 6.02 (5.30–7.44) 6.60 (5.60–7.11) 6.28 (5.78–7.09)
Response rate 55 % 53 % 65 % 60 % 41 %
Pretreatment 14-3-3η (ng/ml) 0.50 (0.16–4.95) 1.05 (0.19–7.75) 1.16 (0.20–9.06) 0.47 (0.13–2.14) 0.70 (0.17–1.89) 0.42 (0.16–14.55) 0.23 (0.09–3.03)b 4.02 (0.46–19.77) 1.05 (0.30–9.46) 1.56 (0.20–11.58)
1-yr 14-3-3η (ng/ml) 0.33 (0.10–1.45) 0.62 (0.14–3.11) 0.75 (0.14–2.96) 0.30 (0.13–1.17) 0.37 (0.11–0.62) 0.28 (0.07–18.33) 0.13 (0.08–0.75)b 1.52 (0.28–5.57) 1.24 (0.11–1.85) 1.27 (0.11–5.08)
Pretreatment CRP (mg/ml) 0.73 (0.15–3.12) 1.14 (0.26–3.40) 0.62 (0.14–5.01) 1.14 (0.40–5.32) 0.36 (0.06–0.83) 0.18 (0.08–1.34) 0.92 (0.14–2.18) 2.67 (0.40–3.50) 2.97 (0.56–5.22) 1.04 (0.33–2.98)
1-yr CRP (mg/ml) 0.03 (0.01–0.09)b 0.09 (0.02–0.37) 0.04 (0.02–0.13)a 0.14 (0.07–1.22) 0.05 (0.02–0.13) 0.12 (0.03–0.31) 0.01 (0.00–0.030)c 0.03 (0.01–0.18) 0.03 (0.02–0.16) 0.04 (0.03–0.28)
EULAR-defined good response Y N Y N Y N Y N Y N
Patients (n) 101 43 30 19 16 4 40 8 15 12
Pretreatment DAS28-ESR 5.32 (4.33–6.45) 5.77 (4.70–6.55) 5.33 (4.33–6.03) 5.32 (4.32–6.77) 4.21 (3.83–5.03) 4.42 (3.32–5.37) 5.02 (4.37–6.61) 5.75 (4.83–6.02) 6.60 (5.74–7.25) 6.10 (5.53–6.60)
Response rate 70 % 61 % 80 % 83 % 56 %
Pretreatment 14-3-3η (ng/ml) 0.62 (0.16–5.02) 1.48 (0.20–12.72) 0.61 (0.12–3.61) 0.70 (0.24–5.84) 0.65 (0.12–1.03) 1.05 (0.20–14.82) 0.37 (0.16–7.33) 10.34 (0.19– > 20) 1.05 (0.30–8.16) 1.56 (0.20–14.02)
1-yr 14-3-3η (ng/ml) 0.28 (0.10–1.51)b 0.80 (0.27–5.99) 0.45 (0.11–1.45) 0.36 (0.22–1.41) 0.30 (0.10–0.47)c 7.39 (0.53– > 18.33) 0.18 (0.08–2.02)b 3.42 (0.39– > 20) 1.24 (0.11–1.85) 1.35 (0.19–9.06)
Pretreatment CRP (mg/ml) 0.96 (0.21 – 3.35) 0.64 (0.23 –3.08) 0.80 (0.27 – 5.33) 0.68 (0.30 – 4.20) 0.16 (0.05–0.80) 0.33 (0.10–1.34) 1.10 (0.20–3.11) 0.60 (0.16–2.99) 2.18 (0.77–4.28) 1.04 (0.26–3.58)
1-yr CRP (mg/ml) 0.03 (0.01 – 0.12)c 0.11 (0.03 – 0.50) 0.05 (0.02 – 0.14)a 0.13 (0.07 – 1.50) 0.04 (0.02–0.24) 0.13 (0.03–0.22) 0.01 (0.00–0.05)a 0.06 (0.02–1.36) 0.03 (0.02–0.16) 0.07 (0.02–0.28)
  1. Abbreviations: ADA adalimumab, CRP C-reactive protein; DAS28-ESR Disease Activity Score in 28 joints with erythrocyte sedimentation rate, EULAR European League Against Rheumatism, MTX methotrexate, TCZ tocilizumab, TOF tofacitinib
  2. Values shown are median (interquartile range)
  3. a p < 0.001
  4. b p < 0.01
  5. c p < 0.05